NEW YORK--(BUSINESS WIRE)--
(NYSE: PFE) will present data across its infectious disease portfolio at the upcoming IDWeek 2024 congress, held in Los Angeles from October 16-19, 2024. Data in 49 abstracts from company- and collaborator-led studies, will highlight the advances Pfizer is making in helping prevent and treat infectious diseases.
“Pfizer is at the forefront of vaccine and therapeutic development in respiratory and infectious diseases,” said Annaliesa Anderson, Ph.D., Senior Vice President and Head, Vaccine Research and Development, Pfizer. “IDWeek 2024 provides a crucial platform to showcase our innovative advancements and engage with the scientific community, as we work to effectively tackle the ongoing challenge posed by infectious diseases.”
"As we approach another respiratory virus season, the importance of preventive vaccines and treatments to help keep us healthy is more apparent than ever,” said Luis Jodar, Ph.D., Chief Medical Affairs Officer, Vaccines/Antivirals, Pfizer. “We’re excited to present new, meaningful data that we hope will help further inform healthcare providers.”
Pfizer will present research from its robust infectious disease portfolio, covering RSV, COVID-19, pneumococcal disease, Lyme disease, meningococcal disease, and serious bacterial and fungal infections. Details for Pfizer-sponsored, investigator-sponsored and collaborative research oral and poster presentations are below:
Title/Abstract Number |
Presenting
|
Date/Time
|
Location
|
ORAL & LATE-BREAKING PRESENTATIONS |
|||
580 - Pharmacokinetics (PK) and Safety of Nirmatrelvir/Ritonavir (NMV/r) in Non-Hospitalized Symptomatic Pediatric Patients Ages 6 Years and Older with COVID-19 Who Are at Increased Risk of Progression to Severe Disease (EPIC-Peds) |
Jacqueline Gerhart, PhD |
Oct 19
|
403 A |
88 - Efficacy of Nirmatrelvir/Ritonavir in High-Risk Trial Participants With Prior SARS-CoV-2 Infection or Vaccination: A Pooled Analysis |
John M. McLaughlin, PhD |
Oct 17
|
411 |
165 - Real-world Abrysvo vaccine effectiveness (VE) against Respiratory Syncytial Virus (RSV)-related severe acute respiratory infection (ARI) hospitalizations and emergency department (ED) visits—Kaiser Permanente of Southern California (KPSC), November 2023-April 2024 |
Sara Tartof, PhD, MPH, (KPSC)* |
Oct 17
|
403A |
571 – Safety and Immunogenicity of Coadministered Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine With and Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age |
Rahsan Erdem, MD
|
Oct 19
|
408 A |
POSTER PRESENTATIONS |
|||
COVID-19 |
|||
P - 1194 - Comparison of COVID-19 Inpatient Burden in Hospitalized Children Age < 5years, by SARS-CoV-2 Variant
|
Kathleen M. Andersen, PhD MSc |
Oct 18
|
Hall J & K |
P - 1906 - Early COVID-19 and Severity of Subsequent Omicron Infection in Ontario, Canada |
Caroline Kassee, MPH (Sinai Health)*
|
Oct 19
|
Hall J & K
|
P - 1977 - Six-Month Trajectory of Symptoms of COVID-19 Fatigue by Age and BNT162b2 COVID-19 Vaccination Status: A Prospective Study Among Symptomatic US Adults Testing Positive for SARS-CoV-2 at a National Retail Pharmacy
|
Manuela Di Fusco, PhD |
Oct 19
|
Hall J & K |
P - 2047 - Public Health Impact and Economic Value of an Additional Dose of Pfizer-BioNTech XBB.1.5-adapted COVID-19 Vaccine for Older Adults in the United States |
Alon Yehoshua, PharmD, MS |
Oct 19
|
Hall J & K |
P - 2048 - COVID-19 XBB.1.5 vaccine uptake based on state vaccine registries compared to national survey data |
Angela Cook, MS |
Oct 19
|
Hall J & K |
P - 2054 - Effectiveness of a Single COVID-19 mRNA Vaccine Dose in Individuals Previously Infected with SARS-CoV-2: A Systematic Review
|
Hannah R. Volkman, PhD, MPH
|
Oct 19
|
Hall J & K |
P - 2060 - Effectiveness of BNT162b2 COVID-19 Vaccination Against Long COVID Among Older Adults: A Nationwide Study |
Manuela Di Fusco, PhD
|
Oct 19
|
Hall J & K
|
P - 2062 - COVID-19 XBB.1.5-adapted vaccine uptake in immunocompromised individuals using tokenized state vaccine registries |
Matthew A. Brouillette, MPH |
Oct 19
|
Hall J & K |
P - 2017 - Patient Reported Outcomes of Nirmatrelvir/Ritonavir Treatment for High-risk, Nonhospitalized Adults with Symptomatic COVID-19 |
Ashley S. Cha-Silva, PharmD, MS |
Oct 19
|
Hall J & K |
Lyme Disease |
|||
P - 599 - 6-Valent, OspA-Based VLA15 Lyme Disease Vaccine Candidate Against Lyme Borreliosis in a Healthy Pediatric and Adult Study Population: A Phase 2 Study Update |
James H. Stark, PhD |
Oct 17
|
Hall J & K |
P - 1287 - Incidence of Symptomatic Lyme Borreliosis in Nine European Countries, 2018−2022 |
Frederick Angulo, DVM PhD |
Oct 18
|
Hall J & K |
P - 1291 - Racial disparities in Lyme disease among beneficiaries of US Medicaid and Medicare |
L. Hannah Gould, PhD, MS, MBA |
Oct 18
|
Hall J & K |
P - 1293 - Healthcare Costs Associated with Lyme Disease in a U.S. Insured Population |
Holly Yu, MSPH |
Oct 18
|
Hall J & K |
Meningococcal Disease |
|||
P - 1299 - Epidemiology of Invasive Meningococcal Disease in the United States: Review of Recent Data and Identified Risk Factors |
Jessica Presa, MD |
Oct 18
|
Hall J & K |
P - 1304 - Public Health Impact of changes to Meningococcal vaccination platform in the United States |
Katharina Schley, Dr. rer pol. |
Oct 18
|
Hall J & K |
Pneumococcal disease |
|||
P - 8 - Assessment of 13-valent pneumococcal conjugate vaccine effectiveness among people living with HIV in the United States |
Amanda C. Miles, MPH |
Oct 17
|
Hall J & K |
P - 628 - Real-world impact of pneumococcal conjugate vaccines on vaccine serotypes and cross-reacting non-vaccine serotypes |
Kevin Apodaca, MPH |
Oct 17
|
Hall J & K |
P - 629 - The health and economic impact of the PCV15 and PCV20 priming series during the first year of life in the US |
Mark Rozenbaum, PhD, M.B.A |
Oct 17
|
Hall J & K |
Respiratory Syncytial Virus (RSV) |
|||
P - 673 - Respiratory Syncytial Virus (RSV) Hospitalizations During Off-Season Months Among Infants in US |
Amy W. Law, PharmD |
Oct 17
|
Hall J & K |
P - 674 - The Economic Burden of Infant RSV Among US Caregivers |
Amy W. Law, PharmD |
Oct 17
|
Hall J & K |
P - 40 - Impact of case and control selection on influenza vaccine effectiveness (VE) among adults aged 40 years and older hospitalized with acute respiratory illness (ARI) during 2022-2023 using a test negative design (TND): secondary analysis of the North America Multi-Specimen Study |
Negar Aliabadi, MD, MS |
Oct 17
|
Hall J & K |
P - 1204 - Hospitalizations Associated with Respiratory Syncytial Virus (RSV) Illness Among Children and Adolescents in Ontario, Canada |
Sazini Nzula, PhD |
Oct 18
|
Hall J & K |
P - 1205 - Impact of the COVID-19 Pandemic on Hospitalizations Associated with Respiratory Syncytial Virus (RSV) Illness Among Children and Adolescents in Ontario, Canada |
Sazini Nzula, PhD |
Oct 18
|
Hall J & K |
P - 677 - Estimation of Respiratory Syncytial Virus-Attributable Hospitalizations Among Older Adults in Japan between 2015 and 2018: An Administrative Health Claims Database Analysis |
Asuka Yoshida, PhD |
Oct 17
|
Hall J & K |
P - 680 - Estimated Respiratory Syncytial Virus (RSV)-Related Hospitalizations and Deaths Among Adults in Norway between 2010–2019 |
Caihua Liang, MD, PhD |
Oct 17
|
Hall J & K |
P - 682 - The Risk of Cardiorespiratory Events for Up to 180 days Following Respiratory Syncytial Virus (RSV) Infection Hospitalization: A Self-Controlled Case Series Analysis |
Caihua Liang, MD, PhD |
Oct 17
|
Hall J & K |
P – 683 – Estimation of RSV-Attributable Cardiovascular and Respiratory Hospitalizations in Adults in Germany, Between 2015-2019 |
Caroline Beese |
Oct 17
|
Hall J & K |
P - 604 - Preliminary real-world Abrysvo vaccine effectiveness (VE) against Respiratory Syncytial Virus (RSV)-related lower respiratory tract disease (LRTD) hospitalizations and emergency department (ED) visits—Kaiser Permanente of Southern California (KPSC) November 2023-April 2024 |
Negar Aliabadi, MD, MS |
Oct 17
|
Hall J & K |
P - 53 - Trends in Co-administration of Adult Vaccinations in the US Retail Pharmacy Setting |
Reiko Sato, PhD |
Oct 17
|
Hall J & K |
P - 603 - Potential Public Health Impact of Respiratory Syncytial Virus (RSV) Vaccines for Prevention of RSV Among Older Adults in the United States |
Reiko Sato, PhD |
Oct 17
|
Hall J & K |
P - 600 - Efficacy Of a Bivalent RSVpreF Vaccine in Older Adults Across a Second RSV Season |
John Woodside, PhD |
Oct 17
|
Hall J & K |
P - 596 - Immunobridging Demonstrating Effectiveness of the Bivalent Respiratory Syncytial Virus (RSV) Prefusion F Subunit Vaccine in Adults 18-59 Years of Age at High Risk of Severe RSV Disease in a Phase 3 Trial: The C3671023 MONeT Study Results |
Elliot N. DeHaan, MD |
Oct 17
|
Hall J & K |
P - 681 - Estimated Incidence of Respiratory Syncytial Virus (RSV)-Related Hospitalizations for Acute Respiratory Infections (ARIs), including Community Acquired Pneumonia (CAP), in Adults in Germany |
Caihua Liang, MD, PhD |
Oct 17
|
Hall J & K |
P - 605 - Bivalent RSV Prefusion F-Based Subunit Vaccine Generates High and Durable Neutralizing Titers Across an Entire RSV Season Among Older Adults |
Tarek Mikati, MD, MPH |
Oct 17
|
Hall J & K |
P - 595 - Public Health Impact of RSVpreF Vaccination on Older Adult Disease Outcomes |
Daniel Eiras, MD, MPH |
Oct 17
|
Hall J & K |
P - 21 - Comparison of Three RSV Vaccine Lower Respiratory Tract Disease Primary Endpoint Definitions for Adult Vaccine |
Sarah E. Williams, MD. MPH |
Oct 17
|
Hall J & K |
P - 2357 - Respiratory Syncytial Virus (RSV) Disease Burden Among Adults in Primary Care Settings in High-Income Countries: A Systematic Review and Modelling Study |
You Li; multiple Pfizer co-authors
|
Oct 19
|
Hall J & K |
Aztreonam-Avibactam |
|||
P - 105 - Aztreonam-Avibactam Compared with Adjunctive Colistin Combined with Meropenem for the Treatment of Serious Gram-Negative Bacterial Infections: Subgroup Analysis of the Phase 3 REVISIT Study |
Heidi Leister-Tebbe, BSN
|
Oct 17
|
Hall J & K |
P - 1080 Aztreonam-Avibactam Activity Against Gram-negative Bacteria Isolated From Patients with Pneumonia from Europe, Asia, and Latin America (2021–2023) |
Helio S. Sader, MD, PhD, FIDSA
|
Oct 18
|
Hall J & K |
P - 1256 - Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Aztreonam-Avibactam Dosing Regimens |
Susan Raber*, PharmD, MPH
|
Oct 17
|
Hall J & K |
P - 1508 - In Vitro Activity of Aztreonam-Avibactam Against Enterobacterales Isolates Producing Multiple β-lactamases Collected Globally as a Part of the ATLAS Global Surveillance Program From 2018-2022
|
Mark Estabrook*, PhD
|
Oct 17
|
Hall J & K |
P - 1509 - In Vitro Activity of Aztreonam-Avibactam Against Enterobacterales Isolated From Pediatric and Adult Patients Collected During the ATLAS Global Surveillance Program, 2018-2022 |
Mark Estabrook*, PhD |
Oct 18
|
Hall J & K |
Isavuconazole |
|||
P - 1168 - Activity of Isavuconazole and Comparator Agents Against Pediatric Fungal Isolates Collected from 2017–2023 in a Global Surveillance Program |
Marisa Winkler, MD, PhD
|
Oct 17
|
Hall J & K |
Ceftazidime-Avibactam |
|||
P- 1506 - In Vitro Activity of Ceftazidime-Avibactam and Comparator Agents Against Pseudomonas aeruginosa Collected from Patients with Presumed Hospital- and Community-Acquired Respiratory Tract Infections as a Part of the ATLAS Global Surveillance Program 2018-2022 |
Mark Estabrook, PhD
|
Oct 17
|
Hall J & K |
P- 1507 - In Vitro Activity of Ceftazidime-Avibactam Against Enterobacterales Isolates Producing Multiple β-lactamases Collected Globally as a Part of the ATLAS Global Surveillance Program from 2018-2022 |
Mark Estabrook, PhD
|
Oct 17
|
Hall J & K |
* =multiple Pfizer co-authors
Prescribing Information for Pfizer Medicines
Please see full for ABRYSVO® (Respiratory Syncytial Virus Vaccine) or visit and .
Please see full for COMIRNATY® (COVID-19 Vaccine, mRNA) or visit .
Please see full for CRESEMBA® (Isavuconazonium Sulfate) or visit
Please see full for PAXLOVIDTM (Nirmatrelvir and Ritonavir) or visit .
Please see full for PREVNAR 20TM (Pneumococcal 20-valent Conjugate Vaccine) or visit .
Please see full for PREVNAR 13® (Pneumococcal 13-valent Conjugate Vaccine).
Please see full for ZAFICEFTA® (Ceftazidime-Avibactam).
About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at . In addition, to learn more, please visit us on and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at .
DISCLOSURE NOTICE: The information contained in this release is as of October 8, 2024. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about Pfizer’s infectious disease pipeline, in-line products and product candidates, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risk and uncertainties include, among other things, uncertainties regarding the commercial success of Pfizer’s infectious disease products and product candidates; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with interim and preliminary data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any drug applications, biologics license applications and/or emergency use authorization applications may be filed in any jurisdictions for any potential indication for Pfizer’s product candidates; whether and when any such applications that may be pending or filed for any of Pfizer’s product candidates may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether any such product candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of Pfizer’s products or product candidates, including development of products or therapies by other companies; manufacturing capabilities or capacity; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at and .
View source version on businesswire.com:
